Online inquiry

IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4570MR)

This product GTTS-WQ4570MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CXCR4 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001008540.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7852
UniProt ID P61073
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4570MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3097MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ6082MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ6536MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CX-191
GTTS-WQ7355MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ8284MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ12951MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ6366MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ8886MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW